Partial Response to Proton Pump Inhibitors (PPI) Treatment: The Cost to Society and the Burden to the Patient - a Study in the US (REMAIN)
Partial Response to PPI Treatment: The Cost to Society and the Burden to the Patient
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Alabama
-
Leeds, Alabama, United States
- Research Site
-
-
Arizona
-
Pheonix, Arizona, United States
- Research Site
-
Tucson, Arizona, United States
- Research Site
-
-
California
-
Concord, California, United States
- Research Site
-
Lancaster, California, United States
- Research Site
-
Los Banos, California, United States
- Research Site
-
Solana Beach, California, United States
- Research Site
-
-
Delaware
-
Newark, Delaware, United States
- Research Site
-
-
Florida
-
Altamonte Springs, Florida, United States
- Research Site
-
Cocoa, Florida, United States
- Research Site
-
Defuniak Springs, Florida, United States
- Research Site
-
Largo, Florida, United States
- Research Site
-
Maitland, Florida, United States
- Research Site
-
Miami, Florida, United States
- Research Site
-
Naples, Florida, United States
- Research Site
-
Ocala, Florida, United States
- Research Site
-
Orlando, Florida, United States
- Research Site
-
Palm Harbor, Florida, United States
- Research Site
-
Peonia, Florida, United States
- Research Site
-
Tampa, Florida, United States
- Research Site
-
-
Georgia
-
Columbus, Georgia, United States
- Research Site
-
Roswell, Georgia, United States
- Research Site
-
Royston, Georgia, United States
- Research Site
-
Snellville, Georgia, United States
- Research Site
-
-
Illinois
-
Belleville, Illinois, United States
- Research Site
-
-
Indiana
-
Mishawaka, Indiana, United States
- Research Site
-
-
Louisiana
-
Metaire, Louisiana, United States
- Research Site
-
-
Maryland
-
Prince Frederick, Maryland, United States
- Research Site
-
Towson, Maryland, United States
- Research Site
-
-
Missouri
-
Florissant, Missouri, United States
- Research Site
-
Jefferson City, Missouri, United States
- Research Site
-
-
New Jersey
-
Atco, New Jersey, United States
- Research Site
-
Fair Lawn, New Jersey, United States
- Research Site
-
-
North Carolina
-
Cary, North Carolina, United States
- Research Site
-
Elkin, North Carolina, United States
- Research Site
-
New Bern, North Carolina, United States
- Research Site
-
Stanley, North Carolina, United States
- Research Site
-
Statesville, North Carolina, United States
- Research Site
-
-
Ohio
-
Beachwood, Ohio, United States
- Research Site
-
Dayton, Ohio, United States
- Research Site
-
Vandalia, Ohio, United States
- Research Site
-
-
Pennsylvania
-
Aliquippa, Pennsylvania, United States
- Research Site
-
Philadelphia, Pennsylvania, United States
- Research Site
-
-
Rhode Island
-
Warwick, Rhode Island, United States
- Research Site
-
-
South Carolina
-
Charleston, South Carolina, United States
- Research Site
-
-
Tennessee
-
Athens, Tennessee, United States
- Research Site
-
-
Texas
-
Austin, Texas, United States
- Research Site
-
Dallas, Texas, United States
- Research Site
-
Irving, Texas, United States
- Research Site
-
San Antonio, Texas, United States
- Research Site
-
San Marcos, Texas, United States
- Research Site
-
Southlake, Texas, United States
- Research Site
-
-
Utah
-
West Jordan, Utah, United States
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- At least 6 month history of GERD symptoms
- Treated with unchanged optimized PPI treatment for any GERD indication during a consecutive 4 week period
- Remaining GERD symptoms despite optimized PPI treatment
- Able to read and write in US English, and able to comply with study requirements
Exclusion Criteria:
- Patients that have not experienced any GERD symptom improvement at all during PPI treatment
- Involvement in the planning or conduct of the study
- Involvement in any other observational study or in any clinical study at the time of this study or during the last 6 months
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
1
552 GERD patients, partial responders to PPI treatment
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Quality of life, productivity loss, frequency and severity of GERD symptoms, health care resource use
Time Frame: Collected at enrollment visit and at 3 and 6 month follow-up. (Health care resource use is at enrollment visit collected retrospectively 6 months)
|
Collected at enrollment visit and at 3 and 6 month follow-up. (Health care resource use is at enrollment visit collected retrospectively 6 months)
|
|
Utility values
Time Frame: Collected at enrollment visit and at 6 month follow-up.
|
Collected at enrollment visit and at 6 month follow-up.
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Meg Good, i3 Innovus
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- D9120N00005
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.